Netherton Syndrome Pipeline: Industry Insights into Global emerging therapies scenario, Leading Pharma Players, Emerging Trends | DelveInsight

Netherton Syndrome Pipeline Insight represents a class of promising therapies for a rare and severe genetic skin disease. With a significant understanding of genetic defects and pathophysiological mechanisms of Netherton Syndrome, companies are exploring new molecules.

Los Angeles, USA, May 13, 2021 (GLOBE NEWSWIRE) -- Netherton Syndrome Pipeline: Industry Insights into Global emerging therapies scenario, Leading Pharma Players, Emerging Trends | DelveInsight

Netherton Syndrome Pipeline Insight represents a class of promising therapies for a rare and severe genetic skin disease. With a significant understanding of genetic defects and pathophysiological mechanisms of Netherton Syndrome, companies are exploring new molecules.

DelveInsight’s ‘Netherton Syndrome Pipeline Insights’ report draws a complete picture of the Netherton Syndrome pipeline therapies that are under development in pre-clinical as well as different clinical stages of development along with discontinued products and growth prospects across the Netherton Syndrome landscape.

Key takeaways from the Netherton Syndrome Pipeline report:

• Netherton Syndrome Pipeline report offers a comprehensive analysis of 10+ key players and10+ key therapies.

• Netherton Syndrome pipeline comprises BBP-561 (BridgeBio Pharma), LM-030 (LifeMax Laboratories), KB104 (Krystal Biotech), TMB-001 (Timber Pharmaceuticals), ATR-12 (Azitra), and others.

• Out of all the emerging therapies, late-stage products such as LM-030, a topical treatment for Netherton Syndrome, are expected to transform the treatment market.

• LM-030 is currently in Phase II/III pivotal clinical trial development by LifeMax Laboratories. In April 2020, the US Food and Drug Administration (FDA) granted fast track designation to LM-030.

• LM-030 previously received orphan drug designation (ODD) from both the FDA and European Commission as well as rare pediatric disease designation (RPD) from the FDA.

Request for Sample @ Netherton Syndrome Emerging Therapies and Forecast to learn more about the emerging therapy having an advantage

Netherton Syndrome: Overview

Netherton syndrome (NS) is a rare autosomal recessive disease, characterized by congenital ichthyosis, trichorrhexis invaginata, erythroderma, atopic manifestations, high immunoglobulin E levels, hypereosinophilia, and failure to thrive.

The Netherton Syndrome pipeline report offers a rich coverage of therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for Netherton Syndrome across the complete product development cycle, including all clinical and non-clinical stages.

Netherton Syndrome Pipeline Drug Portfolio

Drug	Company	Clinical Phase	MoA	RoA
LM-030	LifeMax Laboratories	Phase II/III	Kallikrein-related peptidase inhibitors	Topical
TMB-001	Timber Pharmaceuticals	Phase II	Retinoic acid receptor agonists	Topical
MSB-6005	MatriSys Bio	Phase I	Microbiome modulators	Topical
KB104	Krystal Biotech	Preclinical	Gene transference	NA
ATR-12	Azitra	Preclinical	Serine peptidase inhibitor kazal-type 5 replacements	Topical
BBP-561	BridgeBio Pharma	Preclinical	Kallikrein 5/7 inhibitors	Topical

Request for Sample to know which drug is expected to outperform @ Netherton Syndrome Pipeline Analysis, Key Companies, and Futuristic Trends

Netherton Syndrome Therapeutics Assessment

The Netherton Syndrome Pipeline report proffers exhaustive insights into active Netherton Syndromepipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.

By Product Type

• Mono

• Combination

By Stage

• Discovery

• Pre-clinical

• IND

• Phase I

• Phase II

• Phase III

• Pre-registration

By Molecule Type

• Small Molecule

• Gene Therapy

• Immunoglobulin fragments

• Monoclonal antibodies

• Skin disorder therapies

By Route of Administration

• Intravitreal

• Topical

• Oral

• Subcutaneous

By Mechanism of Action

• Gene transference

• Kallikrein-related peptidase inhibitors

• Microbiome modulators

• Serine peptidase inhibitor kazal-type 5 replacements

By Targets

• Kallikrein-related peptidase

• Retinoic acid receptor

• Serine peptidase inhibitor kazal-type 5

• Kallikrein

• Serine endopeptidase

By Stage and Route of Administration
By Stage and Product Type

Get in touch with our Business executive for Comprehensive Regulatory Analysis of Pipeline Therapies

The Netherton Syndrome pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs that will help the clients to keep a track of the ongoing trials, recent happenings in the domain.

For more information on emerging drugs, visit Netherton Syndrome Pipeline Analysis

Scope of the Report

Coverage: Global
Key Players: LifeMax Laboratories, Timber Pharmaceuticals, MatriSys Bio, Krystal Biotech, Azitra, BridgeBio Pharma, Dermelix Biotherapeutics, and many more.
Key Netherton Syndrome Pipeline Therapies: LM-030, TMB-001, MSB-6005, KB104, ATR-12, BBP-561, DMX-102, and many more.

Reach out @ Netherton Syndrome Pipeline: Novel therapies and emerging trends

Table of Contents

1	Introduction
2	Executive Summary
3	Netherton Syndrome Overview
4	Netherton Syndrome Pipeline Therapeutics
5	Netherton Syndrome Pipeline Therapeutic Assessment
6	Netherton Syndrome – DelveInsight’s Analytical Perspective
7	In-depth Commercial Netherton Syndrome Pipeline Assessment
8	Netherton Syndrome Collaboration Deals
9	Late Stage Netherton Syndrome Pipeline Products (Phase III and Preregistration)
10	Mid-Stage Netherton Syndrome Pipeline Products (Phase II)
11	Pre-clinical and Discovery Stage Netherton Syndrome Pipeline Products
12	Inactive Netherton Syndrome Pipeline Products
13	Netherton Syndrome Key Companies
14	Netherton Syndrome Key Products
15	Netherton Syndrome Unmet Needs
16	Netherton Syndrome Market Drivers and Barriers
17	Netherton Syndrome Future Perspectives and Conclusion
18	Netherton Syndrome Pipeline Analyst Views
20	Appendix

Visit to know more of what’s covered @ Netherton Syndrome Emerging Therapies

Related Reports

Netherton Syndrome Market
DelveInsight's "Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report.

Netherton Syndrome Epidemiology Forecast
DelveInsight's 'Netherton Syndrome - Epidemiology Forecast to 2030' report.
Multiple Myeloma Market
DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report.

Acquired Hemophilia A Market
DelveInsight's "Acquired Hemophilia A Market Insights, Epidemiology, and Market Forecast-2030" report.

Acromegaly Market
DelveInsight’s ‘Acromegaly-Market Insights, Epidemiology, and Market Forecast–2030’ report.

Adenoid Cystic Carcinom Market
DelveInsight's "Adenoid Cystic Carcinom - Market Insights, Epidemiology, and Market Forecast-2030" report.

Allergic Bronchopulmonary Aspergillosis Market
DelveInsight's "Allergic Bronchopulmonary Aspergillosis - Market Insights, Epidemiology, and Market Forecast-2030" report.

Related Posts

Alagille Syndrome Market
Challenges in the Rare Disease Market
Rare Cancer Market
Angelman Syndrome Medications

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com